MicroRNA-200c Attenuates the Tumor-Infiltrating Capacity of Macrophages.
breast tumor
macrophage
miR
tumor microenvironment
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
22 Feb 2022
22 Feb 2022
Historique:
received:
03
02
2022
revised:
17
02
2022
accepted:
18
02
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
27
3
2022
Statut:
epublish
Résumé
Macrophages constitute a major part of the tumor-infiltrating immune cells. Within the tumor microenvironment, they acquire an alternatively activated, tumor-supporting phenotype. Factors released by tumor cells are crucial for the recruitment of tumor-associated macrophages. In the present project, we aimed to understand the role of hsa-miR-200c-3p (miR-200c) in the interplay between tumor cells and macrophages. To this end, we employed a coculture system of MCF7 breast tumor cells and primary human macrophages and observed the transfer of miR-200c from apoptotic tumor cells to macrophages, which required intact CD36 receptor in macrophages. We further comprehensively determined miR-200c targets in macrophages by mRNA-sequencing and identified numerous migration-associated mRNAs to be downregulated by miR-200c. Consequently, miR-200c attenuated macrophage infiltration into 3-dimensional tumor spheroids. miR-200c-mediated reduction in infiltration further correlated with a miR-200c migration signature comprised of the four miR-200c-repressed, predicted targets PPM1F, RAB11FIB2, RDX, and MSN.
Identifiants
pubmed: 35336722
pii: biology11030349
doi: 10.3390/biology11030349
pmc: PMC8945044
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK2336 / TP06
Références
Sci Rep. 2016 Jan 27;6:19884
pubmed: 26814383
PLoS One. 2012;7(10):e47709
pubmed: 23112837
Front Immunol. 2021 Dec 17;12:799428
pubmed: 34992609
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
PLoS One. 2015 Aug 18;10(8):e0135867
pubmed: 26285119
Oncoimmunology. 2012 Aug 1;1(5):687-693
pubmed: 22934260
Sci Transl Med. 2021 Sep 15;13(611):eabg4328
pubmed: 34524864
BMC Cancer. 2015 Apr 02;15:297
pubmed: 25885099
J Oncol. 2015;2015:865816
pubmed: 25883654
J Exp Clin Cancer Res. 2019 Feb 15;38(1):81
pubmed: 30770776
Oncogene. 2018 Jun;37(23):3151-3165
pubmed: 29540832
Semin Cancer Biol. 2020 Feb;60:214-224
pubmed: 31386907
Oncotarget. 2017 Jun 02;8(39):66629-66640
pubmed: 29029543
BMC Bioinformatics. 2009 Feb 03;10:48
pubmed: 19192299
Nat Commun. 2019 Mar 8;10(1):1135
pubmed: 30850595
Blood. 2015 Feb 19;125(8):e1-13
pubmed: 25573988
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
Immunol Cell Biol. 2018 Jan;96(1):68-80
pubmed: 29359349
Biosci Rep. 2019 Jan 30;39(1):
pubmed: 30622149
J Biol Chem. 2008 Mar 28;283(13):8765-71
pubmed: 18245080
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Genes (Basel). 2021 Feb 12;12(2):
pubmed: 33673143
Mol Ther. 2014 Aug;22(8):1494-1503
pubmed: 24791940
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Mol Med (Berl). 2016 Jun;94(6):629-44
pubmed: 27094812
Oncotarget. 2014 Jan 15;5(1):185-95
pubmed: 24368337
Oncogene. 2015 Jul;34(28):3651-61
pubmed: 25241894
Mol Carcinog. 2017 Dec;56(12):2620-2629
pubmed: 28731284
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S607-15
pubmed: 23838916
Breast Cancer Res. 2011 Apr 18;13(2):R45
pubmed: 21501518
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Adv Exp Med Biol. 2016;930:205-39
pubmed: 27558823
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Cells. 2019 Jul 15;8(7):
pubmed: 31311206
Endocr Relat Cancer. 2013 Aug 23;20(5):R257-67
pubmed: 23878074
Eur Urol. 2021 Oct;80(4):456-466
pubmed: 34175151
Cancer Cell Int. 2018 Mar 09;18:35
pubmed: 29540997
Cell Death Differ. 2016 Jan;23(1):132-45
pubmed: 26068592
Pharm Res. 2021 Aug;38(8):1405-1418
pubmed: 34389916
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
Genes Dev. 2008 Apr 1;22(7):894-907
pubmed: 18381893
Trends Immunol. 2012 Mar;33(3):119-26
pubmed: 22277903
Biomed Pharmacother. 2021 Oct;142:112112
pubmed: 34449319
Biomedicines. 2021 Dec 15;9(12):
pubmed: 34944738
Methods Mol Biol. 2013;1024:157-72
pubmed: 23719949
Mol Biol Cell. 2007 Oct;18(10):3810-9
pubmed: 17652460
J Clin Invest. 2014 Dec;124(12):5109-28
pubmed: 25401471
Cancer Res. 2006 Jan 15;66(2):605-12
pubmed: 16423985
Cell Signal. 2015 Dec;27(12):2506-14
pubmed: 26391653
Front Oncol. 2021 Nov 15;11:766248
pubmed: 34868991
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
Nature. 2008 Sep 4;455(7209):58-63
pubmed: 18668040
Cells. 2019 Nov 21;8(12):
pubmed: 31766495
Int J Mol Sci. 2020 Feb 22;21(4):
pubmed: 32098334
Cell Cycle. 2010 Jan 1;9(1):179-87
pubmed: 20016286
Int J Oncol. 2020 Feb;56(2):407-416
pubmed: 31894326
Int J Cancer. 2014 Sep 15;135(6):1356-68
pubmed: 24615544
Int Immunopharmacol. 2020 Apr;81:106028
pubmed: 31801690
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Nat Commun. 2021 Jul 12;12(1):4262
pubmed: 34253738
Science. 2019 Dec 20;366(6472):
pubmed: 31806698
Biochim Biophys Acta. 2016 Dec;1861(12 Pt B):2069-2074
pubmed: 26825691
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39
pubmed: 29275360
Oncotarget. 2018 Oct 30;9(85):35559-35580
pubmed: 30473751
Biochem Biophys Res Commun. 2016 Feb 5;470(2):397-404
pubmed: 26792722
Exp Hematol Oncol. 2021 Dec 29;10(1):60
pubmed: 34965886
Nature. 2008 Sep 4;455(7209):64-71
pubmed: 18668037
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
J Cell Sci. 2014 Jan 15;127(Pt 2):267-75
pubmed: 24421310
Oncotarget. 2016 Oct 18;7(42):68057-68071
pubmed: 27486976
Nat Commun. 2011;2:282
pubmed: 21505438
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
Ann Surg. 2014 Apr;259(4):735-43
pubmed: 23982750
Genome Biol. 2019 Jan 22;20(1):18
pubmed: 30670076
Cell Mol Immunol. 2009 Oct;6(5):343-52
pubmed: 19887047